Addendum
Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Addendum to Commission A21-150
Report documents
-
Addendum
Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Addendum to Commission A21-150
Dossier assessment
Indication:
Add-on therapy for adults with severe chronic rhinosinusitis with nasal polyps that cannot be adequately controlled with systemic corticosteroids and/or surgery
Result of dossier assessment:
After addendum now hint of considerable added benefit
Additional information
Federal Joint Committee (G-BA)
20-05-2022 A G-BA decision was published.
Project details
- Project no.
- A22-42
- Commission
- Commission awarded on 12.04.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed